Recently synthesized class of vinylphosphonates as potent matrix metalloproteinase (MMP-2) inhibitors

Archiv der Pharmazie

Volumn 337, Issue 2, 2004, Pages 76-80

  Al Quntar, Abed Al Aziz ^a   Baum, Ofir ^a   Reich, Reuven ^a   Srebnik, Morris ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cancer; Matrix Metallo Proteinase; Phosphonates; Structure activity relationships; Vinylphosphonates

Indexed keywords

GELATINASE INHIBITOR; PHOSPHONIC ACID DERIVATIVE; ENZYME INHIBITOR; GELATINASE A; VINYL DERIVATIVE; VINYLPHOSPHONIC ACID;

ARTICLE; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; IN VITRO STUDY; PRIORITY JOURNAL; CELL CULTURE; CHEMOTAXIS; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

CHEMOTAXIS; ENZYME INHIBITORS; HUMANS; MATRIX METALLOPROTEINASE 2; PHOSPHONIC ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; VINYL COMPOUNDS;

EID: 1642388464     PISSN: 03656233     EISSN: None     Source Type: Journal    
DOI: 10.1002/ardp.200300828     Document Type: Article

References (35)

1. A. Powell, L. Matrisian, Curr. Top. Microbiol. Immunol. 1996, 213, 1.
2. P. Brown, Med. Oncol. 1997, 14, 1.
3. A. Yu, R. Hewitt, W. Stevenson, Drugs Aging 1997, 11, 229.
4. I. Collier, S. Wilhem, A. Eisen, B. Marmer, G. Goldberg, J. Biol. Chem. 1988, 263, 6579.
5. S. Wilhem, I. Collier, B. Marmer, A. Eisen, G. Grant, G. Goldberg, J. Biol. Chem. 1989, 264, 17213.
6. L. Denis, J. Verweij, Invest. New Drugs 1997, 15, 175.
7. I. Pergament, R. Reich, M. Srebnik, Bio. Med. Chem. Lett. 2002, 12, 1215.
8. A. Chambers, L. Matrisan, J. Nat. Cancer Inst. 1997, 89, 1260.
9. H. Kawamata, K. Kameyama, Y. Tanaka, L. Nan, W. Barch, W. Stetler-Stevenson, R. Oyasu, Int. J. Cancer 1995, 63, 568.
10. R. Reich, E. Thompson, Y. Iwamoto, G. Martin, J. Deason, G. Fuller, R. Miskin, Cancer Res. 1988, 48, 33073.
11. B. Summers, S. Davidson, Ann. Rep. Med. Chem. 1998, 33, 131.
12. M. Whittaker, F. Floyd, A. Gearing, Chem. Rev. 1999, 99, 2735.
13. B. Davies, D. Miles, L. Happerfield, M. Naylor, L. Bobroe, R. Rubens, F. Balkwill, J. Cancer 1993, 67, 1126.
14. B. Davis, J. Waxman, J. Williams, A. Thomas, F. Balkwill, Cancer Res. 1993, 53, 5365.
15. A. Errico, S. Garbisa, L. Liotta, W. Castronovo, W. Stetler-Stevenson, W. Grgioni, Mod. Pathol. 1991, 4, 239.
16. K. Chapman, I. Kupka, P. Durette, C. Esser, T. Lansza, M. Izquierdo-Martin, L. Niedzwiecki, B. Chang, R. Harrison, W. Hagman, Med. Chem. 1993, 36, 4293.
17. T. Cawston, Pharm. Ther. 1996, 70, 163.
18. M. Bendeck, C. Irvin, M. Reidy, Circ. Res. 1996, 78, 38.
19. K. Gijbels, R. Galary, L. Stienman, Clin. Invest. 1994, 94, 2177.
20. G. Wallace, M. Stansford, R. Whiston, J. Immunology 1996, 89, 53.
21. Y. Morimoto, K. Nishkawa, M. Ohashi, Life Sci. 1997, 61, 795.
22. A. Docherty, A. Lyons, B. Smith, E. Wright, P. Stephens, T. Harris, Nature, 1985, 318, 66.
23. W. Stetler-Stevenson, H. Krurzch, L. Liotta, J. Biol. Chem. 1989b, 264, 17374.
24. W. Johnson, N. Roberts, N. Borkakoti, J. Enz. Inhib. 1987, 2, 1.
25. K. Daralak, R. Miller, M. Spak, A. Spatola, R. Gray, J. Biol. Chem. 1990, 265, 5199.
26. K. Mookhtiar, C. Marlowe, P. Bartlett, Van Wart, H. Biochemistry, 1987, 26, 962.
27. A. Quntar, M. Srebnik, Organic Lett. 2001, 3, 1379.
28. A. Quntar, M. Srebnik, J. Org. Chem. 2001, 66, 6650-6653.
29. A. Quntar, A. Melman, M. Srebnik, Synlett, 2002, 1, 61-64.
30. A. Quntar, A. Melman, M. Srebnik, J. Org. Chem. 2002, 67, 3769-3772.
31. A. Quntar, M. Srebnik Chem. Comm. 2003, 59, 58.
32. A. Quntar, V. Dembitsky, M. Srebnik, Organic Lett. 2003, 5, 357.
33. C. Fink, J. Carlson, C. Boehm, P. McTaggart, Y. Qiao, J. Doughy, V. Ganu, R. Melton, R. Goldberg, Bioorg. Med. Chem. Lett. 1999, 9, 195.
34. S. Sahoo, C. Caldwell, K. Chapman, P. Durette, C. Esser, I. Kopka, S. Polo, K. Sperow, L. Niedzwiecki, B. Chang, R. Harrison, R. Stien, M. MacCoss, W. Hagmann, Bioorg. Med. Chem. Lett. 1995, 5, 2441. (They found a similar effect in the carboxylic acid compounds. When the phenyl groups are replaced by linear alkyl chains, the MMP-2 inhibition improves.)
35. This is consistent with the other studies. When the chain length of phenyl substituents increases, the inhibition improves, (see reference 33)